Literature DB >> 24179073

Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT.

Nitesh Sood1, Anne-Christine H Ruwald, Scott Solomon, James P Daubert, Scott McNitt, Bronislava Polonsky, Christian Jons, Christopher A Clyne, Wojciech Zareba, Arthur J Moss.   

Abstract

OBJECTIVE: The aim of the present study was to assess a possible association between myocardial substrate, implantable cardioverter defibrillator (ICD) shocks, and subsequent mortality.
METHODS: Within the multicentre automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) population (n = 1790), we investigated the association between myocardial substrate, ICD shocks and subsequent mortality using multivariate Cox regression analyses and landmark analyses at 1-year follow-up.
RESULTS: The 4-year cumulative probability of ICD shocks was 13% for appropriate shock and 6% for inappropriate shock. Compared with patients who never received ICD therapy, patients who received appropriate shock had an increased risk of mortality [HR = 2.3 (1.47-3.54), P < 0.001], which remained increased after adjusting for echocardiographic remodelling at 1 year (HR = 2.8, P = 0.001). Appropriate anti-tachycardia pacing (ATP) only was not associated with increased mortality (P = 0.42). We were not able to show an association between inappropriate shocks (P = 0.53), or inappropriate ATP (P = 0.10) and increased mortality. Advanced myocardial structural disease, i.e. higher baseline echocardiographic volumes and lack of remodelling at 1 year, was present in patients who received appropriate shocks but not in patients who received inappropriate shocks or no shocks.
CONCLUSION: In the MADIT-CRT study, receiving appropriate ICD shocks was associated with an increased risk of subsequent mortality. This association was not evident for appropriate ATP only. These findings, along with advanced cardiac structural disease in the patients who received appropriate shocks, suggest that the compromised myocardium is a contributing factor to the increased mortality associated with appropriate ICD shock therapy. Clinical trials.gov identifier: NCT00180271.

Entities:  

Keywords:  Anti-tachycardia pacing; ICD therapy; MADIT-CRT; Mortality; Shocks

Mesh:

Year:  2013        PMID: 24179073     DOI: 10.1093/eurheartj/eht451

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  10 in total

1.  Impact of cardiac resynchronization therapy-defibrillator implantation on the association between body mass index and prognosis in patients with heart failure.

Authors:  Satoshi Yanagisawa; Yasuya Inden; Masayuki Shimano; Naoki Yoshida; Shinji Ishikawa; Hiroyuki Kato; Satoshi Okumura; Aya Miyoshi-Fujii; Tomoyuki Nagao; Toshihiko Yamamoto; Yoshiaki Mizutani; Tadahiro Ito; Makoto Hirai; Toyoaki Murohara
Journal:  J Interv Card Electrophysiol       Date:  2015-05-24       Impact factor: 1.900

Review 2.  The subcutaneous ICD-current evidence and challenges.

Authors:  Kiran Haresh Kumar Patel; Pier D Lambiase
Journal:  Cardiovasc Diagn Ther       Date:  2014-12

3.  The Significance of Shocks in Implantable Cardioverter Defibrillator Recipients.

Authors:  Anthony Li; Amit Kaura; Nicholas Sunderland; Paramdeep S Dhillon; Paul A Scott
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-08

Review 4.  [Catheter ablation of ventricular tachycardia in patients with structural heart disease].

Authors:  F Lindemann; A Darma; G Hindricks
Journal:  Herz       Date:  2022-03-09       Impact factor: 1.443

5.  Antiarrhythmic Drug Therapy to Avoid Implantable Cardioverter Defibrillator Shocks.

Authors:  Jaber Abboud; Joachim R Ehrlich
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-08

6.  Implantable cardioverter defibrillators in octogenarians: clinical outcomes from a single center.

Authors:  D G Wilson; N Ahmed; R Nolan; A Frontera; G Thomas; E R Duncan
Journal:  Indian Pacing Electrophysiol J       Date:  2015-04-01

7.  2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.

Authors:  Bruce L Wilkoff; Laurent Fauchier; Martin K Stiles; Carlos A Morillo; Sana M Al-Khatib; Jesœs Almendral; Luis Aguinaga; Ronald D Berger; Alejandro Cuesta; James P Daubert; Sergio Dubner; Kenneth A Ellenbogen; N A Mark Estes; Guilherme Fenelon; Fermin C Garcia; Maurizio Gasparini; David E Haines; Jeff S Healey; Jodie L Hurtwitz; Roberto Keegan; Christof Kolb; Karl-Heinz Kuck; Germanas Marinskis; Martino Martinelli; Mark McGuire; Luis G Molina; Ken Okumura; Alessandro Proclemer; Andrea M Russo; Jagmeet P Singh; Charles D Swerdlow; Wee Siong Teo; William Uribe; Sami Viskin; Chun-Chieh Wang; Shu Zhang
Journal:  J Arrhythm       Date:  2016-02-01

8.  Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders.

Authors:  Vassilios J Bezzerides; Aifeng Zhang; Ling Xiao; Bridget Simonson; Santosh A Khedkar; Shiro Baba; Filomena Ottaviano; Stacey Lynch; Katherine Hessler; Alan C Rigby; David Milan; Saumya Das; Anthony Rosenzweig
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

9.  Rationale and design of BERLIN VT study: a multicenter randomised trial comparing preventive versus deferred ablation of ventricular tachycardia.

Authors:  Roland Richard Tilz; Karl-Heinz Kuck; Stephan Kääb; Karl Wegscheider; Annette Thiem; Beate Wenzel; Stephan Willems; Daniel Steven
Journal:  BMJ Open       Date:  2019-05-09       Impact factor: 2.692

10.  Prognostic Importance of Defibrillator-Appropriate Shocks and Antitachycardia Pacing in Patients With Mild Heart Failure.

Authors:  Yitschak Biton; Usama A Daimee; Jayson R Baman; Valentina Kutyifa; Scott McNitt; Bronislava Polonsky; Wojciech Zareba; Ilan Goldenberg
Journal:  J Am Heart Assoc       Date:  2019-03-19       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.